Background: Thyroid Eye Disease (TED) is known to alter tissues of the orbital cavity, including the optic nerve. However, its effect on measured global Retinal Nerve Fiber Layer (gRNFL) is not well elucidated. This case evaluates the effect of teprotumumab on gRNFL in a patient with moderate TED. Observations: A 60-year-old female with controlled ocular hypertension and moderate TED received 8 standard IV teprotumumab infusions. Comprehensive ocular evaluations were performed pre-, during-, and post-treatment. Bilateral gRNFL thickness decreased (−10 µm OD; −12 µm OS) at 4 months post-treatment start, persisting at 8 months, but recovered at 20 months. Conclusions and Importance: Teprotumumab treatment in patients with TED led to a transient bilateral decrease in gRNFL thickness, which was restored to baseline levels with no adverse events reported. Monitoring gRNFL changes in teprotumumab-treated patients is crucial as gRNFL thinning indicates retinal ganglion cell damage. Teprotumumab’s ability to dampen the IGF-IR inflammatory cascade may have reduced retinal inflammation, leading to recovery.
References
[1]
Douglas, R.S., Kahaly, G.J., Patel, A., Sile, S., Thompson, E.H.Z., Perdok, R., Fleming, J.C., Fowler, B.T., Marcocci, C., Marinò, M., Antonelli, A., Dailey, R., Harris, G.J., Eckstein, A., Schiffman, J., Tang, R., Nelson, C., Salvi, M., Wester, S., Sherman, J.W., Vescio, T., Holt, R.J. and Smith, T.J. (2020) Teprotumumab for the Treatment of Active Thyroid Eye Disease. The New England Journal of Medicine, 382, 341-352. https://doi.org/10.1056/NEJMoa1910434
[2]
Naik, V.M., Naik, M.N., Goldberg, R.A., Smith, T.J. and Douglas, R.S. (2010) Immunopathogenesis of Thyroid Eye Disease: Emerging Paradigms. Survey of Ophthalmology, 55, 215-226. https://doi.org/10.1016/j.survophthal.2009.06.009
[3]
Smith, T.J., Kahaly, G.J., Ezra, D.G., Fleming, J.C., Dailey, R.A., Tang, R.A., Harris, G.J., Antonelli, A., Salvi, M., Goldberg, R.A., Gigantelli, J.W., Couch, S.M., Shriver, E.M., Hayek, B.R., Hink, E.M., Woodward, R.M., Gabriel, K., Magni, G. and Douglas R.S. (2017) Teprotumumab for Thyroid-Associated Ophthalmopathy. The New England Journal of Medicine, 376, 1748-1761. https://doi.org/10.1056/NEJMoa1614949
[4]
Krieger, C.C., Sui, X., Kahaly, G.J., Neumann, S. and Gershengorn, M.C. (2022) Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease. The Journal of Clinical Endocrinology & Metabolism, 107, e1653-e1660. https://doi.org/10.1210/clinem/dgab824
[5]
Yoon, J.S. and Kikkawa, D.O. (2022) Thyroid Eye Disease: From Pathogenesis to Targeted Therapies. Taiwan Journal of Ophthalmology, 12, 3-11. https://doi.org/10.4103/tjo.tjo_51_21
[6]
Li, L., Eter, N. and Heiduschka, P. (2015) The Microglia in Healthy and Diseased Retina. Experimental Eye Research, 136, 116-130. https://doi.org/10.1016/j.exer.2015.04.020
[7]
Cui, X., Wang, F. and Liu, C. (2023) A Review of TSHR-and IGF-1R-Related Pathogenesis and Treatment of Graves’ Orbitopathy. Frontiers in Immunology, 14, 1062045. https://doi.org/10.3389/fimmu.2023.1062045
[8]
Khong, J.J., McNab, A.A., Ebeling, P.R., Craig, J.E. and Selva, D. (2015) Pathogenesis of Thyroid Eye Disease: Review and Update on Molecular Mechanisms. British Journal of Ophthalmology, 100, 142-150. https://doi.org/10.1136/bjophthalmol-2015-307399
[9]
Otero-Marquez, O., Fayad, M., Pinhas, A., Chui, T.Y.P., Rosen, R.B. and Reddy, H.S. (2022) Retinal Surface Macrophage Changes in Thyroid Eye Disease before and after Treatment with Teprotumumab. Case Reports in Ophthalmological Medicine, 2022, 5275309. https://doi.org/10.1155/2022/5275309
[10]
Potvin, A.R.G.G., Pakdel, F. and Saeed, P. (2023) Dysthyroid Optic Neuropathy. Ophthalmic Plastic and Reconstructive Surgery, 39, S65-S80. https://doi.org/10.1097/IOP.0000000000002555
Sears, C.M., Azad, A.D., Amarikwa, L., Pham, B.H., Men, C.J., Kaplan, D.N., Liu, J., Hoffman, A.R., Swanson, A., Alyono, J., Lee, J.Y., Dosiou, C. and Kossler, A.L. (2022) Hearing Dysfunction after Treatment with Teprotumumab for Thyroid Eye Disease. American Journal of Ophthalmology, 240, 1-13. https://doi.org/10.1016/j.ajo.2022.02.015
[13]
Chu, M., Sung, J., Song, M., Song, A. and Song, J. (2022) Intraocular Pressure Improvement in Patients Receiving Teprotumumab for the Treatment of Thyroid Eye Disease: A Case Series. Journal of Medical Case Reports, 16, 195. https://doi.org/10.1186/s13256-022-03375-x
[14]
Sen, S., Chen, S., Feng, B., Iglarz, M. and Chakrabarti, S. (2012) Renal, Retinal and Cardiac Changes in Type 2 Diabetes Are Attenuated by Macitentan, a Dual Endothelin Receptor Antagonist. Life Sciences, 91, 658-668. https://doi.org/10.1016/j.lfs.2012.03.032
[15]
Hoang, T.D., Nguyen, N.T., Chou, E. and Shakir, M.K. (2021) Rapidly Progressive Cognitive Decline Associated with Teprotumumab in Thyroid Eye Disease. BMJ Case Reports, 14, e242153. https://doi.org/10.1136/bcr-2021-242153
[16]
Arroba, A.I., Campos-Caro, A., Aguilar-Diosdado, M. and Valverde, Á.M. (2018) IGF-1, Inflammation and Retinal Degeneration: A Close Network. Frontiers in Aging Neuroscience, 10, 203. https://doi.org/10.3389/fnagi.2018.00203
